Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 345:1305-1310, 2001.

Bernat A, Herbert JM. Protamine sulphate inhibits pentasaccharide (SR80027)-induced bleeding without affecting its antithrombotic and anti-factor Xa activity in the rat. Haemostasis 26:195-202, 1996.

Bijsterveld NR, Moons AH, Boekholdt SM, van Aken BE, Fennema H, Peters RJ, Meijers JC, Buller HR, Levi M. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 106:2550-2554, 2002.

Boneu B, Necciari J, Cariou R, Sie P, Gabaig AM, Kieffer G, Dickinson J, Lamond G, Moelker H, Mant T, et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man. Thromb Haemost 74:1468-1473, 1995.

Boshkov LK, Kirby A, Heuschkel M. Pharmcokinetics of fondaparinux by anti-Xa levels and clinical response to anticoagulation in a 4-month old congenital cardiac patient with heparin-induced thrombocytopenia (HIT) and established venous thrombosis transitioned from argatroban to fondaparinux [abstr]. Blood 104 (Suppl 1):104b, 2004.

Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Van den Berg-Segers AE, Cariou R, Leewenkamp O, Lensing AW. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349:1695-1702, 2003.

Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW. Fondaparinux or enoxa-parin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 140:867-873, 2004.

Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 116: 492-499, 1983.

Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AGG, Egberts JF, Lensing AW. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo controlled trial. BMJ 332:325-329, 2006.

D'Amico EA, Villaca PR, Gualandro SF, Bassitt RP, Chamone DA. Successful use of Arixtra in a patient with paroxysmal nocturnal hemoglobinuria, Budd-Chiari syndrome and heparin-induced thrombocytopenia. J Thromb Haemost 1:2452-2453, 2003.

D'Angelo A, Valle PD, Fattorini A, Luciano C. Disappearance of anti-PF4/heparin antibodies under prolonged fondaparinux administration in a patient with DVT associated with LMWH-induced thrombocytopenia. Thromb Haemost 95:573-575, 2006.

Daud AN, Ahsan A, Iqbal O, Walenga JM, Silver PJ, Ahmad S, Fareed J. Synthetic heparin pentasaccharide depolymerization by heparinase I: molecular and biological implications. Clin Appl Thromb Hemost 7:58-64, 2001.

Dempfle CE. Minor transplacental passage of fondaparinux in vivo. N Engl J Med 350: 1914-1915, 2004.

Donat F, Duret JP, Santoni A, Cariou R, Necciari J, Magnani H, De Greef R. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacoki-net 41 (Suppl 2):1-9, 2002.

Elalamy I, Lecrubier C, Potevin F, Abdelouahed M, Bara L, Marie JP, Samama M. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb Haemost 74:1384-1385,1995.

Eriksson BI, Lassen MR. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 163:1337-1342, 2003.

Eriksson BI, Bauer KA, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 345:1298-1304, 2001.

Gerotziafas GT, Depasse F, Chakroun T, Van Dreden P, Samama MM, Elalamy I. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma. Blood Coagul Fibrinolysis 15:149-156, 2004.

Grabowski EF, Bussel JB. Pediatric experience with fondaparinux in deep venous thrombosis. Blood 108 (Suppl 1):274a-275a, 2006.

Greinacher A, Pötzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Hae-most 71:247-251, 1994.

Greinacher A, Alban S, Dummel V, Franz G, Mueller-Eckhardt C. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost 74:886-892, 1995.

Greinacher A, Gopinadhan M, Guenther JU, Omer-Adam MA, Strobel U, Warkentin TE, Papastavrou G, Weitschies W, Helm CA. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol 26:2386-2393, 2006.

Grootenhuis PD, Westerduin P, Meuleman D, Petitou M, van Boeckel CA. Rational design of synthetic heparin analogues with tailor-made coagulation factor inhibitory activity. Nat Struct Biol 2:736-739,1995.

Haase M, Bellomo R, Rocktaeschel J, Ziemer S, Kiesewetter H, Morgera S, Neumayer HH. Use of fondaparinux (ARIXTRA) in a dialysis patients with symptomatic heparin-induced thrombocytopenia type II. Nephrol Dial Transplant 20:444-446, 2005.

Harenberg J. Treatment of a woman with lupus and thromboembolism and cutaneous intolerance to heparins using fondaparinux during pregnancy. Thromb Res 119: 385-388, 2007.

Harenberg J, Jorg I, Fenyvesi T. Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica 89:1017-1018, 2004.

Hirsch K, Ludwig RJ, Lindhoff-Last E, Kaufmann R, Boehncke WH. Intolerance of fondaparinux in a patient allergic to heparin. Contact Dermatitis 50:383-384, 2004.

Hirsh J, O'Donnell M, Weitz J. New anticoagulants. Blood 105:453-463, 2005.

Huvers F, Slappendel R, Benraad B, van Hellemondt G, van Kraaij M. Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid. Neth J Med 63:184-186, 2005.

Jappe U, Juschka U, Kuner N, Hausen BM, Krohn K. Fondaparinux: a suitable alternative in cases of delayed-type allergy to heparins and semisynthetic hepar-inoids? A study of 7 cases. Contact Dermatitis 51:67-72, 2004.

Klaeffling C, Piechottka G, Daemgen-von Brevern G, Mosch G, Mani H, Luxembourg B, Lindhoff-Last E. Development and clinical evaluation of two chromogenic substrate methods for monitoring fondaparinux sodium. Ther Drug Monit 28: 375-381, 2006.

Kovacs MJ. Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost 93:999-1000, 2005.

Kubitza D, Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs 99:999-1000, 2006.

Kuo KH, Kovacs MJ. Fondaparinux: a potential new therapy for HIT. Hematology 10: 271-275, 2005.

Lagrange F, Vergnes C, Brun JL, Paolucci F, Nadal T, Leng JJ, Saux MC, Banwarth B. Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra) in the dually perfused human cotyledon in vitro. Thromb Haemost 87:831-835, 2002.

Lam LH, Silbert JE, Rosenberg RD. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 69:570-577,1976.

Lassen MR, Bauer KA, Eriksson MI, Turpie AGG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 359:1715-1720, 2002.

Linkins LA, Weitz JI. New anticoagulant therapy. Annu Rev Med 56:63-77, 2005.

Mazzolai L, Hohlfeld P, Spertini F, Hayoz D, Schapira M, Duchosal MA. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood 108:1569-1570, 2006.

Mehta SR, Steg PG, Granger CB, Bassand JP, Faxon DP, Weitz JI, Afzal R, Rush B, Peters RJ, Natarajan MK, Velianou JL, Goodhart DM, Labinaz M, Tanguay JF, Fox KA, Yusuf S. Randomized, blinded trial comparing fondaparinux with unfractio-nated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: A Randomized Evaluation (ASPIRE) Pilot Trial. Circulation 111:1390-1397, 2005.

Parody R, Oliver A, Souto JC, Fontcuberta J. Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. Haematologica 88:ECR32, 2003.

Petitou M, Herault JP, Bernat A, Driguez PA, Duchaussoy P, Lormeau JC, Herbert JM. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 398: 417-422,1999.

Piovella F, Barone M, Beltrametti C, Piovella C, D'Armini AM, Marzani FC, Arici V, De Amici M, Barco SL, Castellani G, Langer M. Efficacy of fondaparinux in the treatment of heparin-induced thrombocytopenia with venous thromboembolism: reduction of thromboembolic burden, normalization of platelet count and disappearance of anti-platelet factor 4/heparin antibodies [abstr]. Blood 108 (Suppl 1):173a, 2006.

Pouplard C, Couvret C, Regina S, Gruel Y. Development of antibodies specific to polyanion-modified platelet factor 4 during treatment with fondaparinux. J Thromb Haemost 3:2813-2815, 2005.

Rauova L, Zhai L, Kowalska MA, Arepally GM, Cines DB, Poncz M. Role of platelet surface antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood 107:2346-2353, 2006.

Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: a phase II evaluation. Circulation 102:2726-2731, 2000.

Rosenberg RD, Lam L. Correlation between structure and function of heparin. Proc Natl Acad Sci USA 76:1218-1222,1979.

Rosenberg RD, Armand G, Lam L. Structure-function relationships of heparin species. Proc Natl Acad Sci USA 75:3065-3069, 1978.

Savi P, Chong BH, Greinacher A, Gruel Y, Kelton JG, Warkentin TE, Eichler P, Meuleman D, Petitou M, Herault JP, Cariou R, Herbert JM. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 105:139-144, 2005.

Smogorzewska A, Brandt JT, Chandler WL, Cunningham MT, Hayes TE, Olson JD, Kottke-Marchant K, Van Cott EM. Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing. Arch Pathol Lab Med 130:1605-1611, 2006.

Turpie AGG. Use of selective factor Xa inhibitors in special populations. Am J Orthop 31:11-15, 2002.

Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 162:1833-1840, 2002a.

Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomized double-blind trial. Lancet 359: 1721-1726, 2002b.

Turpie AGG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 344:619-625, 2001.

Utikal J, Peitsch WK, Booken D, Velten F, Dempfle CE, Goerdt S, Bayerl C. Hypersensi-tivity to the pentasaccharide fondaparinux in patients with delayed-type heparin allergy. Thromb Haemost 94:895-896, 2005.

Walenga JM, Bara L, Petitou M, Samama M, Fareed J, Choay J. The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity. Thromb Res 51:23-33, 1988.

Warkentin TE, Cook RJ, Marder VJ, Sheppard JI, Moore JC, Eriksson BI, Greinacher A, Kelton JG. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic therapy with fondaparinux or enoxaparin. Blood 106: 3791-3796, 2005.

Warkentin TE, Jay RM, Makris M, Kelton JG. Platelet-activating anti-platelet factor 4/ polyanion antibodies without preceding heparin therapy: a transient autoimmune disorder resembling heparin-induced thrombocytopenia ("spontaneous HIT") [abstr]. Blood 108:311a-312a, 2006.

Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux [letter]. N Engl J Med 2007; in press.

Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost 96:274-284, 2006.

Weitz JI, Buller HR. Direct thrombin inhibitors in acute coronary syndromes: present and future. Circulation 105:1004-1011, 2002.

Wijesiriwardana A, Lees DA, Lush C. Fondaparinux as anticoagulant in a pregnant woman with heparin allergy. Blood Coagul Fibrinolysis 17:147-149, 2006.

Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA (Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators). Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354:1464-1476, 2006a.

Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295:1519-1530, 2006b.

How To Win Your War Against Allergies

How To Win Your War Against Allergies

Not Able To Lead A Happy Life Because Of Excessive Allergies? Want To Badly Get Rid Of Your Allergy Problems, But Are Super Confused And Not Sure Where To Even Start? Don't Worry, Help Is Just Around The Corner Revealed The All-In-One Power Packed Manual Containing Ample Strategies And Little-Known Tips To Get Rid Of Any Allergy Problems That Are Ruining Your Life Learn How You Can Eliminate Allergies Completely Reclaim Your Life Once Again

Get My Free Ebook

Post a comment